Our cell-based vaccine production platform offers a solid and reliable foundation for innovative vaccines for infectious diseases and oncolytic applications and is anchored by our Vero GMP cell line.
Vero cells, initially isolated and immortalized from the kidney of an African Green Monkey in the early 1960s, have evolved into the gold standard for viral vaccine production. They are renowned for their exceptional quality, yield, and safety.
Intravacc has harnessed Vero cells for viral vaccine development since 1987. Our cGMP-grade, regulatory-approved Vero cell line forms the backbone of our viral vaccine production process. Clients worldwide rely on this platform for large-scale commercial vaccine manufacturing. Notably, we have successfully produced virus seed lots and clinical batches on Vero cells, including multiple generations of poliovirus, non-polio enteroviruses like EV71 and EV D68, and respiratory syncytial virus (RSV).
We’ve established the Vero cell platform for viral vaccine production processes at lab and pilot scales, facilitating rapid proof-of-concept development. Moreover, the platform is fully scalable, with Vero cells cultured on microcarriers in bioreactors, making them ideal for larger-scale production. We also employ downstream processes (DSP) to ensure vaccine purity through, for example, host cell protein removal. Finally, we provide 'ready to use' cGMP-grade cell banks and comprehensive technology transfer packages for immediate project initiation. Currently, most of our viral vaccine development projects are built on the Vero cell platform.
Learn more about our Vero cells.
View which of our vaccine candidates build on Cell-Vacc.
With the Vero cell line at our disposal, Intravacc has the capability to propagate a wide range of viruses, whether from clinical isolates or through virus rescue from plasmid DNA. Our commitment to scientific excellence and rigorous standards ensures that our cell-based vaccine production platform is a dependable resource for effective vaccine development.
Collaborate with us to advance your vaccine projects.
Seamlessly transform your vaccine concepts into reality. Our specialized CDMO services support your work across all our production platforms.
You can send us an email:
info@intravacc.nl
Reach out to Business Development:
BD@intravacc.nl
Or pick up the phone:
+31 30 792 03 00
You can also just fill out the contact form on the right.
We look forward to hearing from you!
